
Ki20227
CAS No. 623142-96-1
Ki20227( Ki 20227 | Ki-20227 )
Catalog No. M15358 CAS No. 623142-96-1
A potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 50 | In Stock |
![]() ![]() |
5MG | 87 | In Stock |
![]() ![]() |
10MG | 147 | In Stock |
![]() ![]() |
25MG | 284 | In Stock |
![]() ![]() |
50MG | 507 | In Stock |
![]() ![]() |
100MG | 707 | In Stock |
![]() ![]() |
500MG | 1431 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameKi20227
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.
-
DescriptionA potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM; weakly inhibits KDR, c-Kit, and PDGFRβ with IC50 of 12, 451, and 217 nM, respectively, no activty against Flt-3, c-Src, Fyn, EGFR, FGFR2, Met, Btk, PKA, and PKCα (IC50>1,000 nM); inhibits the M-CSF-dependent cell growth, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
-
In VitroKi20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively. Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. Cell Viability Assay Cell Line:M-NFS-60 cells, HUVEC cells, human A375 melanoma cells Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:72 hours Result:100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively.Cell Viability Assay Cell Line:RAW264.7 cell lysate Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:1 hourResult:Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
-
In VivoKi20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice. Animal Model:4-week-old male F344/NJcl-rnu rats.Dosage:10, 20, and 50 mg/kg Administration:Orally; once per day for 20 days Result:Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas.
-
SynonymsKi 20227 | Ki-20227
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
RecptorCSF-1R,VEGFR2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number623142-96-1
-
Formula Weight480.5362
-
Molecular FormulaC24H24N4O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 7.2 mg/mL
-
SMILESO=C(NC(C1=NC=CS1)C)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2OC
-
Chemical NameUrea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ohno H, et al. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
2. Ohno H, et al. Eur J Immunol. 2008 Jan;38(1):283-91.
3. Uemura Y, et al. J Neuroimmunol. 2008 Mar;195(1-2):73-80.
molnova catalog



related products
-
JNJ-28312141
JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.
-
Vimseltinib
DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
-
Chiauranib
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects.